Schedule an Appointment
Elminda Ltd

Elminda Ltd

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.

Book a Conference Call
Get More Information

Elminda, Ltd

Location: Herzliya, Israel

Sector: Life Sciences

Industry: MedTech

Add to Shortlist
Express Interest

Headquarters and R&D in Israel, US subsidiary.

Elminda is a unique neuro-technology company harnessing data science and Artificial Intelligence to change the way we diagnose and treat brain disease. We have a team of world-class multi-disciplinary scientists, physicians, engineers and business entrepreneurs.

Wide IP coverage and the world’s largest database of brain function information.

25+ active sites (US, China, Europe, Israel)

 

 

Inside view to Florida’s largest retirement community use of BNA technology 

 

 

Recent News

Solving a problem – Critical need

Today, brain diagnosis and treatment selection is largely based on subjective measures or imaging modalities that shed little light on brain function. Elminda’s BNA™ technology provides an objective, reliable and repeatable way of measuring the brain functions

 

Market size

Brain diseases affect more than 2 billion people. It is a $3 trillion problem. We currently address 2 Major Societal & Clinical Needs:  Brain Wellness or Annual Brain Checkup – enables early detection of potential abnormalities due to aging or incidence and monitor progress and impact of interventions. Total market exceeds 1 Billion people worldwide.

Brain Disorders:  depression, as a first market, affects 322 Million people worldwide

 

The team

Our multi-disciplinary team combines expertise in neuroscience, signal processing, big data analytics, artificial intelligence, engineering, medicine, cloud computing as well as business and finance with proven track record

 

Intellectual Property

Wide coverage and protection of intellectual property with 61 patents & patents applications, 3 trade secrets, and the world’s largest & rapidly growing proprietary human brain function with clinical information database

 

Competitive Edge

Creating a new category in the industry and significant barrier for entry, leading a digital brain health revolution

MARKET

Regulation / Certification

FDA /CE cleared solution

Unique database

400K brain recordings of EEG/ ERP/ BNA with clinical information

Clinical grade database for comparison of healthy and pathological datasets

Initial market adoption

Initial market adoption with available insurance reimbursement codes

Demonstration of high-value business model

Install base systems across various demographics – US/Europe/China/Israel

 

SCIENCE & TECHNOLOGY

Signal and data quality

Automatic real time signal quality assessment, noise detection and cleaning using machine learning

High stability and reproducibility

Standardization and harmonization

Provides standardization in a highly un-regulated field

Makes EEG install based compatible (hardware independence)

Clinical validation

Core methodology is supported by over 10,000 publications

Provides cognitive functions assessment with electrophysiology

Provides clinical neuro-markers for prediction and diagnosis

Comprehensive approach and methodologies suitable for multiple clinical needs

Dr. Arun Menawat, Chairman of the Board

An accomplished history of executive leadership success in the healthcare industry leading companies from start‐up to fast growth success. Dr. Menawat served as the President, CEO and Chairman of Novadaq Technologies Inc., leading the company from start‐up, to successful IPO, to leading developer and provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures.

Served as President and CEO at Cedara Software, which was sold to Merge Healthcare and ultimately to IBM for their Watson program. Ph.D. in Chemical (Bio) Engineering from the University of Maryland, while concurrently completing a fellowship in biomedical engineering at the NIH, Executive MBA from Kellogg School of Management. In 2014, Dr. Menawat was named the EY Ontario Entrepreneur of the Year in the health sciences category.

 

Mr. Ronen Gadot, CEO

The first investor in elminda, recognizing the significant unmet need in the diagnostics and treatment of brain related disorders. Entrepreneurial leader of creative solutions that are making a difference, he was selected by the World Economic Forum to serve on the council for the future of neurotechnologies and brain sciences.

Previously held several positions at Silicon Valley based Applied Materials, co‐founded Philips’ Global Corporate Venture arm, making Philips one of the most active corporate investors in Israel, and CEO of the European subsidiary of one of Philips portfolio companies, SHL Telemedicine. Former F‐16 pilot and member of the IAF Aerobatic Team, holds a BSc in Industrial Engineering and an MBA from INSEAD.

 

Prof. Amir Geva, CTO

Founded elminda in 2006 following over 30 years of brain related research conducted as part of his academic and entrepreneurial career. Prof. and head of the Biomedical Laboratory of the Electrical, & Computer Engineering department at the Ben Gurion University and a visiting Prof. at the Technion Institute of Technology. Experienced entrepreneur and founder of companies with a significant managerial track record. Accomplished scientist, with years of brain and EEG research and experience initiated at the research unit of the Israeli Navy.

A worldwide expert in biomedical signal processing and pattern recognition and pioneer in the use of Artificial Intelligence in healthcare with dozens of academic publications in scientific journals and books. Holds a B.Sc, M.Sc and D.Sc. in Electrical and Computer Engineering and Biomedical engineering from the Technion Institute of Technology.

 

Mr. Geri Katz, CFO

Vast experience as a CFO of private and publicly traded companies, including PowerDsine, (Nasdaq: PDSN) as well as prior COO and CEO of private companies. Experience includes a successful IPO and M&A. BA in Economics and Accounting, CPA

 

Dr. Roni Sharon, Medical Director

Board‐Certified Neurologist in the United States and Israel, and currently Director of Headache and Facial pain at Sheba Medical Center. He completed a fellowship at Harvard Medical School’s Brigham and Women’s Hospital in Boston, MA following a residency in Neurology at Mount Sinai Beth Israel in New York, NY. He has years of clinical experience, with many academic publications, and lectures internationally on the subjects of neurology, brain health and wellness.

 

Dr. Ziv Peremen, VP Medical & Pharma Solutions

An experienced leader with a diverse background in physics, cognitive neuroscience and business development. A lecturer at Tel Aviv University. Holds a BSc in Physics and Philosophy and a PhD in Cognitive Neuroscience from Tel Aviv University.

 

Mrs. Tanya Damm Bokobza, VP Wellness Solutions

An award winning Industrial Designer & experienced entrepreneur. Previously served as the CEO of a B2B2C, 3D printing pioneering platform as a Google sponsored Entrepreneur. Holds a BFA with honors in Industrial design from RISD and MA Innovation Studies from The academy of art Bezalel.

 

Mrs. Chen Golan, VP HR & Operations

A hands‐on logistics professional with a multi‐tasking skill set which includes planning, directing, producing and coordinating activities and operations. Specializes in mass media communications.


ioTech International, Inc

ioTech International, Inc

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.

 

 

Book a Conference Call
Get More Information

ioTech International, Inc

Location: Boca Raton, Florida

Sector: Life Sciences.

Add to Shortlist
Express Interest

ioTech’s patented, next-generation, antimicrobial technology provides superior germ-killing products for massive global markets across multiple industries. Initial focus is on the professional dental market in the U.S. and Canada for the prevention and treatment of periodontal disease. Products are sold direct to dentists (for resale to patients) and direct to dental patients. Global rollout to follow.

 

ioTech has harnessed the power of molecular iodine (the only biocidal or germ-killing species of iodine), boosting its strength to 150 times greater availability than possible with commonly available povidone iodine.

 

Simultaneously, the Company’s patented technology suppresses all other non-biocidal forms of iodine to negligible levels. The resulting stable formulations are non-staining, do not sting or burn and are a generational advance over existing technology. With unprecedented levels of safety and effectiveness, they are rapidly effective against all classes of microorganisms (bacteria, viruses, fungi and spores). They also prevent the development of bacterial resistance, a major drawback of antibiotics and most other antimicrobials, rendering them useless with over-use

  • Robust, proprietary, patented, core technology with hundreds of antimicrobial applications.
  • Commercial sales have begun for $3 billion plus professional dental market opportunity with unmet need.
  • Highly positive initial market acceptance to first professional dental products.
  • Broad product pipeline to be developed both internally and through strategic partners to create a robust IP portfolio.
  • Licensing royalties available across multiple market sectors (agriculture, healthcare, consumer products) with a direct-to-market strategy for the dental industry. Successful evaluation completed and licensing discussions in progress with a highly successful consumer products company to develop and market multiple consumer products based on the Company’s technology. Licensing discussions are also ongoing with an $11 billion healthcare company.
  • Potential to disrupt several billion dollar global markets including $750 billion in food spoilage costs, $30 billion nonfood consumer market and $3 billion periodontal market
  • Low cost of sourcing material and manufacturing resulting in gross margins between 80-90%.
  • Experienced management team with comprehensive experience in commercializing medical technology products.

More Effective
ioTech products rapidly and completely kill all known pathogens (bacteria, viruses, fungi and spores)

 

Very Affordable
With our dental products, patients self-treat at home as part of their daily home oral hygiene regimen. They can avoid expensive dental visits, surgery, loss of teeth and their replacement. Raw material costs are so low that for all markets, ioTech products can compete effectively on price alone.

 

No Bacterial Resistance
Other  antimicrobial agents allow  bacterial resistance to develop and lose their effectiveness so they can only be used for short duration. ioTech products do not permit bacteria to become resistant.

 

Safety and Environmental Impact
ioTech products are for inanimate surfaces or are applied externally. They are safe for humans and cause no discomfort. They are also environmentally friendly to animals, aquatic life and plants.

 

Lack of Toxicity and Side Effects
Our active ingredient is an essential nutrient which is required for optimal health. Insufficient iodine in our diets results in iodine deficiency diseases.

 

Suitable for Long Term Use
Unlike other products which are restricted to short term use (because of bacterial resistance build-up or side effects), our products are so safe that they can be used daily by patients for their entire lives.

Herb Moskowitz, D.D.S., Chairman, CEO and Co-Founder

Dr. Moskowitz has 40 years of healthcare experience, including 23 years in the clinical practice of dentistry. He is the principal shareholder and co-author of ioTech’s core patent application.

He has co-founded and served as Chairman and Chief Executive Officer of two publicly-traded medical technology companies as well as a Board Member to five. Dr. Moskowitz has also provided venture capital and guidance to launch additional technology companies.

 

Edward J. Quilty, Director, CEO (designate)

Mr. Quilty has an extensive and distinguished history with start-ups and has been responsible for the successful introduction of numerous, innovative, medical products. He has served as Chairman and Chief Executive Officer of five public and private medical technology companies over the last 20 years, including Derma Sciences, MedChem Products, and Palatin Technologies.

Mr. Quilty has led financing and M&A transactions approaching $2 billion during that period.

 

Jack Kessler, Ph.D., Chief Scientist, Co-Founder, Chairman, Scientific Advisory Board

Dr. Kessler’s previous experience includes Manager, Research and Development, Amoco Biotechnology; Senior Scientist, New Technology Evaluation, Hoffman La Roche; Founder, Chairman and Chief Scientific Officer, Symbollon Corp.; Co-Founder, Chief Scientific Officer, Director of R&D for ioTech International.

He is the holder of 22 U.S. patents, co-authored ioTech’s patent applications, authored a textbook chapter on Iodine, and dozens of other articles in peer-reviewed scientific publications.

 

Jay Chung, J.D. Executive V.P., Legal and Financial, Director

Mr. Chung is the current V.P. and CFO of a leading regional management company. He is a seasoned attorney with an emphasis on International Law and strong background in economics, business development and finance.

 

Scientific Advisory Board

Includes the Deans of two U.S Dental Schools, The President of the American Academy of Otolaryngology, an Internationally acclaimed Professor of Periodontics and the President of the Society of Oral Implantologists and a Pioneer in iodine chemistry.


Kalos Therapeutics Inc

Kalos Therapeutics Inc

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.

 

 

 

 

Book a Conference Call
Get More Information

Kalos Therapeutics Inc

Location: Phoenix, AZ

Sector: Life Sciences.

Add to Shortlist
Express Interest

Kalos Therapeutics, Inc. is a biomedical company developing a class of therapeutic peptides to fight cancer.  These peptides have already shown significant clinical activity in cardiovascular, cancer and veterinary indications. Kalos’ drugs replicate a natural, anti-proliferative activity by disrupting tubulin activity.

Our lead drug candidate, KTH-222, is a safe, non-toxic drug which may be used as 1) a front-line therapy, 2) a long-term maintenance therapy or 3) a co-therapy which reduces time to chemo resistance and minimizes chemo side-effects.  KTH-222 reduces tumor size while addressing complications, such as metastasis, thereby, allowing the patient to maintain a quality of life not seen with chemo therapy treatments alone.

Initial cancer markets include:  pancreatic, ovarian, prostate, lung and liver.  An animal division will develop drugs for the treatment of cancer and renal disease, congestive heart failure and epistaxis.

Business Documents

MG cp Summary

KTH-222 – Human Cancer

Breakthrough technology – Novel therapeutic for unmet medical need in pancreatic cancer and associated complications like metastases.

 

Orphan Drug Designation – U.S. Orphan designation qualifies the sponsor to a seven-year period of market exclusivity upon approval of the drug. Sponsor may apply for FDA orphan research grants, a waiver of Prescription Drug User Fee Act filing fees andtax credits for clinical research costs.

 

Low to no toxicity, well tolerated and limited to no side effects – Our drug could be used as a lead therapy, a second line active therapy or potentially the first long-term maintenance therapy for many cancers.  Based on its low/no toxicity, there is little risk of resistance and when used in combination, chemo amounts can be reduced with an improved quality of life for the patient.

 

KTH-222/variants – Canine Cancer

Pet owners are reluctant to subject their pets to chemotherapy based on Quality of Life (QOL), costs, and outcomes. KTH-222 is well tolerated, fewer, if any side effects, reduces primary tumor, address complications like metastases, improves QOL and can be used in combination with chemo should the owner desire.

 

KTH-222/variant – Retinal disease

Ease of delivery – Kalos has explored delivery of this therapy in retinal disease as a topical, delivered as a viscous drop, or applied to film. The goal is to eliminate or reduce injections into the eye as site fatigue is a problem and compliance of patients is difficult. This approach can be adapted in multiple eye diseases and KTH-222 should follow the pathway of testing previously completed with the parent peptide where vision was restored in AMD simulated animal models.

 

KTV-111 – Animal Epistaxis, Equine athletes

Focused on fluid removal to reduce bleeding in Equine Athletes – A well tolerated, potassium sparing approach to fluid removal to stop bleeding, additive benefits: regeneration of microtubules, and improvement of compromised heart function providing therapeutic benefits to the horses, while being compliant with regulations in each sport or event.

Quality-of-Life Safer, less toxic approach to slowing cancer with fewer side effects.

 

Safety/Toxicity Well tolerated. It is similar to amino acids found in the heart.

 

Addresses metastasis Our drug recognizes the metastasis and attacks these as small tumors.  This is not being addressed by other therapies, and can lead to a long-term maintenance therapy and increased survival.

 

Synergistic Can be used in conjunction with existing therapies to provide a better quality-of-life and progression free survival.

 

Reduction of drug resistance When used synergistically with chemo, the amount of chemo used can be reduced thereby allowing a longer treatment cycle.

George Colberg, Co-Founder, CEO, Chairman

Mr. Colberg is a seasoned corporate finance and management executive. He was CEO of Primary Inc., a company where he pioneered the plan for acquisitions and the business model initiating early efforts in personalized medicine, electronic medical record meshed with patient data and billing and the advanced use of diagnostics. Prior to Primary Care he was a Vice President at the Financial Group managing syndications and equity investment research while raising in excess of $100 million.

 

Mr. Colberg developed the corporate philosophy of Kalos, identified and shaped the strategy behind the primary products, and the commercialization plan for Kalos. He raised the seed round, series A and B rounds and grant financing totaling $3.5 million. He recruited the executive team and scientific advisory board and oversees the clinical development plan.  Mr. Colberg set the strategy for securing US and EU IP patents and the Orphan Drug Designation.

 

Mr. Colberg completed his Bachelor of Science from San Diego State University and attended University California, Berkeley  for a Certification as a Biomedical Executive.

 

Jay Merritt, MD, President and Chief Medical Officer

Dr. Merritt is a medical oncologist with over 20 years’ experience as a biotechnology executive. He most recently served as President and Chief Medical Officer at Adventrx Pharmaceuticals.  He was founding CEO of Imagine Pharmaceuticals, a venture stage company with a small molecule approach to facilitate drug uptake across the blood brain barrier.

 

He began his industrial career at the Upjohn Company leading early stage oncology and infectious diseases clinical research and he played a key role in launching Upjohn’s HIV research program. He subsequently held senior management positions at IDEC Pharmaceuticals (now Biogen Idec), Viagene Inc. and Introgen Therapeutics, successfully advancing ground-breaking biological modalities such as therapeutic monoclonal antibodies for cancer and rheumatologic diseases, and retroviral and adenoviral gene transfer technologies for cancer and HIV.

 

Dr. Merritt graduated from Johns Hopkins University and received an M.D. from the University of Vermont. He trained in Internal Medicine and Medical Oncology at the University of Wisconsin where he was also appointed Assistant Scientist in the Biophysics Laboratory.

 

Michael Kozlowski, PhD, Chief Science Officer

Dr. Michael Kozlowski is an Associate Professor at the Arizona College of Optometry (AZCOPT) at Midwestern University and CSO at Kalos therapeutics. Prior to Kalos, Dr. Kozlowski spent over 25 years in drug discovery and development for several clinical applications including cancer, age-related macular degeneration, and CNS disorders, and has over 40 peer-reviewed publications and over a dozen issued US patents.

 

He has worked with large pharmaceutical (Pfizer, BMS) and biotechnology companies (Geron, Telik, Axiom, Kreido Laboratories).  Dr. Kozlowski has held positions ranging from Research Scientist to Chief Scientific Officer.

 

Dr. Kozlowski holds a BS in Biology from Caltech, a PhD in Neuroscience from the University of California at Irvine, and an OD from the New England College of Optometry.


ThermaGenix Inc

ThermaGenix Inc

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

ThermaGenix Inc

Location: Natick, MA

Sector: Life Sciences.

Add to Shortlist
Express Interest

ThermaGenix is committed to empowering scientists all over the world with the highest performing Polymerase Chain Reaction (PCR) additives. Our innovative and universal PCR additives ThermaStop™, ThermaGo™ and ThermaStop-RT™ augment polymerase specificity and fidelity, enhancing quantitative end-point data accuracy and analysis and achieving more homogeneous amplicons for downstream applications.

 

These technologies significantly enhance analysis of RNA substrates as well as DNA substrates. From genotyping to Gibson assembly, next generation sequencing sample preparation to diagnostics, ThermaGenix technology will maximize PCR and RT-PCR performance.

Business Documents

MG cp Summary

ThermaStop™, ThermaGo™ and ThermaStop-RT™ prevent DNA Polymerases and Reverse Transcriptases from acting outside of  precise temperature ranges, thereby minimizing spurious side reactions and off-target activity. TGX is the first company to offer patented molecular reagents that control the key enzymes in very specific temperature ranges- which results in High-Precision PCR.

 

Key Features of ThermaStop:

• Replaces Hot-Start, cheaper & more effective – benefit for all forms of PCR

• Stabilizes Taq Polymerase for Extended Periods of Time- benefit for PCR

• Prevents mis-priming during reverse transcription of RNA

• Enhances Multiplexing – benefit for PCR

• Acts as a Cold Stop – benefit for NGS

• First Hot-Start for RT-PCR – benefit for NGS

 

Key Features of ThermaGo:

• First reagent to suppress product-product interactions during amplification

• Works with both antibody hot start and chemical hot start

• Enhances End-Point Genotyping using Symmetric PCR

• Suppresses chimera formation – benefit for NGS and Gibson assembly

 

Key Features of ThermaStop-RT:

• Provides Superior Hot-Start for RT-PCR

• Significantly improves Sensitivity and Specificity in RT-PCR

• Provides for Significant Increase in RNA Yields as reported and far better One-Step or Two-Step RT-PCR results

Entry into Global PCR Marketplace:

VERY Large and Growing Global Markets. ThermaGenix products are unique and value-adding for all aspects of PCR marketplace.

 

Entry in Global Next-Gen Sequencing (NGS) Markets:

VERY Large and Growing Global Markets. ThermaGenix products are unique and value-adding for all aspects of NGS marketplace. It is estimated that use addition of ThermaGenix reagents in NGS Product and Library preparation that approx.. 25% of NGS costs can by eliminated- saving over $100M annually.

 

Entry into VERY Large and Expanding Liquid Biopsy Marketplace:

ThermaGenix represents an “Intel-Inside” like opportunity to have an investment into the largest growth opportunity to come to Life Science/Cancer Diagnostics in the last decade, and for years to come.

Peter J Coassin – President and CEO

Mr Coassin is an experienced and successful inventor, entrepreneur and leader.  Since graduation Mr. Coassin has invented technologies and worked with leading academic scientists (Hubert Koester, Edwin Southern, John Fenn, Roger Tsien, Ron Davis and most recently Lawrence Wangh) to bring to market many different technologies including DNA Synthesizers, Peptide Synthesizers, DNA Arrays, Capillary Electrophoresis based DNA sequencing, cellular technologies and miniaturization, advanced microscopy and now, truly revolutionary additives to improve critical biotechnology enzyme processes.

 

Mr Coassin has worked within large Fortune 500 companies to produce products (Millipore, Beckman-Coulter, Vertex Pharmaceuticals) as well as a range of startups including CoWest Instruments – Sold to Millipore 1985, Aurora Biosciences –   Sold to Vertex in 2001, Aurora Discovery – sold to Beckman in 2006, Aurora Biotechnologies – merged to Nexus 2009 and sold to Brooks Automation 2011.

 

 

Lawrence J Wangh, Founder and CSO

Professor Lawrence, received his undergraduate degree in biology at Brandeis University in 1968 and his Ph.D. in biochemistry from The Rockefeller University in 1973.  He then went to England as a Helen Hay Whitney Fellow and work at the Medical Research Council laboratories in Cambridge and London.  In 1977 he returned to the Biology Department of Brandeis University to teach courses in developmental biology, reproductive biology, and evolution.  In parallel he established a laboratory aimed at doing basic research in those same fields.  In the course of that work he and his laboratory colleagues invented a novel method for non-symmetric amplification of very small amounts of DNA.

 

From 1997 through 2016, with approximately 10 million dollars of support from grants and biotechnology companies, he and his team invented a suite of synergistic technologies that enhanced their new PCR method and its use in many fields, including quantitative measurements of DNA and RNA in single cell, highly informative single-tube diagnosis of cancer gene targets, and detection of numerous infectious diseases – including extensively drug resistant tuberculosis.

 

After nearly forty years on the Brandeis faculty, Professor Wangh and his team: Aquiles Sanchez, Ph.D., John Rice M.S., and Kenneth Pierce, Ph.D. launched ThermaGenix, Inc. in 2017 in order to commercialize their revolutionary PCR reagents and methods. ThermaGenix is committed to enhancing the quality of life by selling its technologies for high precision analysis of very small quantities of nucleic acids to researchers, biotechnologists, and medical professionals worldwide.

 

 

Charles Powell, Chief Commercial Officer

Mr. Powell has spent the majority of his professional career in a variety of Life Science Sales and Marketing roles and assignments starting out as a field-sales representative with Beckman Instruments. Mr. Powell joined Aurora Discovery in May 2004 as Vice President, Sales and Marketing- eventually becoming Chief Commercial Officer and Director.

 

Aurora evolved over 7 years – merging with Nexus Biosystems in 2009 before being bought by Brooks Automation in 2011. In October 2015 Mr. Powell bought the Aurora Business back from Brooks Automation. In January 2017 Mr. Powell joined Thermagenix as Chief Commercial Officer.


Sequella Inc.

Sequella Inc.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Sequella Inc.

Location: Rockville, MD

Sector: Life Sciences .

Add to Shortlist
Express Interest

Sequella is a private, clinical stage pharmaceutical company that addresses the challenge of antibiotic resistant bacterial diseases by discovery and development of first in class antibiotics with novel mechanisms of action.

Business Documents

MG cp Summary

The clinical stage drugs produced by Sequella Inc. are SQ109 and sutezolid: both are being independently advanced for the treatment of drug resistant tuberculosis (MDR-TB).

SQ109 completed a successful MDR-TB registration trial in Russia: application for commercial approval will be filed and Sequella will receive product royalties. Both SQ109 and sutezolid are ready to enter pivotal trials in the US/EU that, if successful, will lead to NDA filing for accelerated registration in both territories. Registration in the U.S. of SQ109 for MDR-TB will provide Sequella with a priority review voucher (PRV) that can be monetized as part of a financing or at receipt: average sales price of PRV since inception is $178M. SQ109 has also been evaluated in an early stage clinical trial for treatment of gastritis (Helicobacter pylori in-fections).

SQ641 is in late pre-clinical development for the treatment of Clostridium difficile induced diarrhea, a deadly healthcare and community acquired infectious disease. Sequella also has a large chemical library of small molecule compounds created around active pharmacophores that can be screened on other important antibiotic resistant bacteria.

Late-stage products (reduced risk) – One drug, SQ109, has successfully completed a registration trial in Russia, meeting both safety and efficacy endpoints; sutezolid has completed a successful Phase 2a study in TB patients, with excellent early bactericidal activity

 

Drugs that address drug-resistant bacterial infections with novel mechanisms of action – Few companies are developing drugs for antibiotic resistant infections, despite clear need: in particular, few companies have or are developing new drugs for TB and no companies are developing drugs for H. pylori, which our drugs address

 

TB will always be treated with ≥ 3 drugs because of resistance development – Companies that are developing new TB drugs are looking for other compatible drugs with which to pair their drugs and make a new safer and more effective drug regimen, so all companies are collaborators, not competitors

 

Drugs in development are either new or improved versions of existing drugs – SQ109 is a new drug that acts in multiple ways to kill TB, no other drugs in clinical development kill TB in the same way. Sutezolid is an improved version of Zyvox (linezolid) and is expected to have similar efficacy and a better safety profile that allows for long term dosing. SQ641 is from a whole new class of antibiotics never before commercialized.

Carol A. Nacy, Chief Executive Officer Dr. Nacy is an accomplished scientist and businesswoman, with 20 years of basic science research and science management in academic settings (Fellow of the American Academy of Microbiology) and an additional 25 years of starting companies and leading science for product development in three U.S.-based biotechnology companies. She and the management team took her first company public on NASDAQ and her second company was acquired by a large biotechnology company. Her passion is in understanding and devising ways to prevent or treat infectious diseases that are global health threats, especially antibiotic resistant bacteria. She co-founded Sequella in 1997 and has led her team to discover and develop several novel antibiotics now in clinical trials that address diseases that infect billions of people worldwide, kill millions of people annually, and are underserved by pharmaceutical and biotechnology companies.

 

Mark Rampy, Chief Business Officer  Dr. Rampy has over twenty years of experience in the biotechnology and pharmaceutical sectors, including leadership roles at early stage and venture-backed companies, and mid-large cap public pharmaceutical/biotechnology companies.  His areas of expertise include business/corporate strategy, business development, structure, negotiation and closing of complex licensing transactions and strategic alliances, as well as technology and product development.  Prior to Sequella, he was CEO of several start-ups (Theraly Pharmaceuticals, and CohBar, Inc), VP Business Development Biologics and Specialty Products, Teva Pharmaceuticals, Founder and Chief Business Officer of CoGenesys, Inc. a company which was acquired by Teva. Prior to CoGenesys, he was with Human Genome Sciences, Inc. for eleven years, in positions of increasing responsibility in R&D and Business Development, the most senior of which was Head of Business Development.​

 

David Mc Neeley, MD, Chief Medical Officer Dr, Mc Neeley is an MD and specialist in pediatric infectious diseases, public health and tropical medicine. He was on the faculty of Weill Cornell Medical Center in the Division of Pediatric Infectious Diseases, working primarily in HIV and TB clinics, as well as general pediatric infectious disease clinic and in-hospital consultations, including rotations through Memorial Sloan-Kettering Medical Center. He has worked extensively in international health settings, including serving as medical director of an all-service hospital and an extensive community health program serving nearly 250,000 people. He conducted clinical and field research in bacterial infections, tuberculosis, human immunodeficiency virus infection and parasitic diseases such as schistosomiasis and filariasis. For the past 14 years, Dr. Mc Neeley has worked in anti-infective drug development (antibiotics, antivirals, and anti-parasitic drugs). For the past 14 years, Dr. Mc Neeley has worked in anti-infective drug development (antibiotics, antivirals, and anti-parasitic drugs) in large pharmaceutical companies (Johnson & Johnson, Novartis) and brought the first new TB drug, bedaquiline, through the clinic and to worldwide registration for J&J.

 

Leo Einck, VP Industry Affairs Dr. Einck has been building companies for the last 33 years: he was the 1st employee of Hemispherix and built out manufacturing facilities and executed clinical trials; he was the 8th employee of EntreMed and managed the relationship with a Harvard research group whose technology enabled the company to have an initial public offering; and he founded Sequella and Sequella Global TB Foundation with Dr. Nacy and has participated in all aspects of growing the company. His current role includes managing the GMP manufacturing and testing of Sequella’s antibiotics and research on TB diagnostics.